利用本國健保資料庫為材料，針對 2001 年至 2007 年成年糖尿病藥物新使用 族群進行分析，在最長七年的研究期間內，有使用sulfonylureas 藥物的族群相較於 未使用者，平均年齡較高且平均追蹤時間也較長。而納入研究後，有使用
sulfonylureas 藥物族群在心血管與糖尿病藥物的使用人數比例均高於未使用 sulfonylureas 藥物族群。而使用過 sulfonylureas 藥物的族群中，曾使用過 glyburide 者在年齡、性別分布上和未使用過glyburide 者沒有明顯差異，但是在心血管藥物 與糖尿病藥物的使用人數比例上以前者較高。
心肌梗塞事件與心臟血管手術事件的分析結果顯示，整體而言，在心肌梗塞 事件前30 天或 365 天曾暴露過 sulfonylureas 藥物者相較於未暴露者，發生心肌梗 塞事件的風險並未較高。但是若將各種sulfonylureas 分開後再進行評估，則發現在 事件前365 天使用過 gliclazide 的病人，發生心肌梗塞事件的風險較高。過去大部 分的文獻均指出，gliclazide 對心血管系統較不具影響，因此我們的研究結果尚需 後續研究進行更深入的探討。而根據本研究結果，sulfonylureas 藥物在糖尿病藥物 的新使用者上，似乎不會增加心肌梗塞的風險。
在心衰竭事件上，sulfonylureas 藥物無論在事件前 30 天或 365 天的迴歸模式 均未達到統計顯著意義，顯示其和心衰竭事件並沒有特別的相關性。然而將 sulfonylureas 藥物分開後再進行分析，發現在心衰竭事件前 365 天使用過 gliquidone 的病人，發生心衰竭事件的風險較高。過去的文獻鮮少針對此議題進行探討。
在中風事件上，分析結果顯示 sulfonylureas 藥物在中風事件前 30 天可能具有 保護性的作用，其中以gliclazide 與 glimepiride 較為顯著。而在 365 天模式分析的 結果，發現上述兩個藥物的保護性效果可能受到對中風事件具有不良影響的 glyburide 稀釋。而若進一步以累積暴露劑量分析，上述兩個藥物的保護性效果則 再度達到顯著，顯示其保護性的效果就長期而言與暴露程度相關。
參考資料
1. Association of American Diabetes. Diagnosis and Classification of Diabetes Mellitus. Diabetes Care 2009;32:S62-S7.
2. 行政院衛生署統計資訊網. 2009. (Accessed 4/25, 2009, at
<http://www.doh.gov.tw/statistic/index.htm>.)
3. American Diabetes Association. 2009. (Accessed 4/235, 2009, at
<http://www.diabetes.org/diabetes-heart-disease-stroke.jsp>.)
4. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. Lancet
1998;352:837-53.
5. Nathan DM, Buse JB, Davidson MB, et al. Medical management of hyperglycemia in type 2 Diabetes: a consensus algorithm for the initiation and adjustment of therapy.
Diabetes Care 2008.
6. Feinglos MN, Bethel MA. Therapy of type 2 diabetes, cardiovascular death, and the UGDP. Am Heart J 1999;138:S346-52.
7. Riveline JP, Danchin N, Ledru F, Varroud-Vial M, Charpentier G. Sulfonylureas and cardiovascular effects: from experimental data to clinical use. Available data in humans and clinical applications. Diabetes Metab 2003;29:207-22.
8. Wild S, Roglic G, Green A, Sicree R, King H. Global prevalence of diabetes:
estimates for the year 2000 and projections for 2030. Diabetes Care 2004;27:1047-53.
9. Roglic G, Unwin N, Bennett PH, et al. The burden of mortality attributable to diabetes: realistic estimates for the year 2000. Diabetes Care 2005;28:2130-5.
10. Curtis L. Triplitt CAR, Willam L. Isley. Diabetes Mellitus. In: Dipiro JT, ed.
Pharmacotherapy: a Pathophysiologic Approach. 6 ed. New York: McGraw-Hill;
2005:1334-62.
11. Groop LC, Pelkonen R, Koskimies S, Bottazzo GF, Doniach D. Secondary failure to treatment with oral antidiabetic agents in non-insulin-dependent diabetes. Diabetes Care 1986;9:129-33.
12. Bagust A, Beale S. Deteriorating beta-cell function in type 2 diabetes: a long-term model. QJM 2003;96:281-8.
13. Matthews DR, Cull CA, Stratton IM, Holman RR, Turner RC. UKPDS 26:
Sulphonylurea failure in non-insulin-dependent diabetic patients over six years. UK Prospective Diabetes Study (UKPDS) Group. Diabet Med 1998;15:297-303.
sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus: progressive requirement for multiple therapies (UKPDS 49). UK Prospective Diabetes Study
(UKPDS) Group. JAMA 1999;281:2005-12.
15. DeFronzo RA, Ferrannini E, Simonson DC. Fasting hyperglycemia in
non-insulin-dependent diabetes mellitus: contributions of excessive hepatic glucose production and impaired tissue glucose uptake. Metabolism 1989;38:387-95.
16. Selvin E, Marinopoulos S, Berkenblit G, et al. Meta-analysis: glycosylated hemoglobin and cardiovascular disease in diabetes mellitus. Ann Intern Med 2004;141:421-31.
17. Yamagishi S, Imaizumi T. Diabetic vascular complications: pathophysiology, biochemical basis and potential therapeutic strategy. Curr Pharm Des 2005;11:2279-99.
18. 第二型糖尿病照護指引. 2006. (Accessed 5/22, 2009, at
http://www.endo-dm.org.tw/dia/dia_book.asp?id=1.)
19. Kempen JH, O'Colmain BJ, Leske MC, et al. The prevalence of diabetic retinopathy among adults in the United States. Arch Ophthalmol 2004;122:552-63.
20. Wu AY, Kong NC, de Leon FA, et al. An alarmingly high prevalence of diabetic nephropathy in Asian type 2 diabetic patients: the MicroAlbuminuria Prevalence (MAP) Study. Diabetologia 2005;48:17-26.
21. Bucala R, Mitchell R, Arnold K, Innerarity T, Vlassara H, Cerami A. Identification of the major site of apolipoprotein B modification by advanced glycosylation end products blocking uptake by the low density lipoprotein receptor. J Biol Chem 1995;270:10828-32.
22. Haffner SM, Lehto S, Ronnemaa T, Pyorala K, Laakso M. Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N Engl J Med 1998;339:229-34.
23. Schramm TK, Gislason GH, Kober L, et al. Diabetes patients requiring
glucose-lowering therapy and nondiabetics with a prior myocardial infarction carry the same cardiovascular risk: a population study of 3.3 million people. Circulation
2008;117:1945-54.
24. Savage PJ. Cardiovascular complications of diabetes mellitus: what we know and what we need to know about their prevention. Ann Intern Med 1996;124:123-6.
25. Malmberg K, Yusuf S, Gerstein HC, et al. Impact of diabetes on long-term prognosis in patients with unstable angina and non-Q-wave myocardial infarction:
results of the OASIS (Organization to Assess Strategies for Ischemic Syndromes) Registry. Circulation 2000;102:1014-9.
26. Evans JM, Wang J, Morris AD. Comparison of cardiovascular risk between
patients with type 2 diabetes and those who had had a myocardial infarction: cross sectional and cohort studies. BMJ 2002;324:939-42.
27. Lee CD, Folsom AR, Pankow JS, Brancati FL. Cardiovascular events in diabetic and nondiabetic adults with or without history of myocardial infarction. Circulation 2004;109:855-60.
28. HC G. Cardiovascular disease. In: Gerstein HC H, ed. Evidence-based Diabetes Care. Canada: BC Decker; 2001:488-514.
29. Haffner SM, Agostino RD, Jr., Saad MF, et al. Carotid artery atherosclerosis in type-2 diabetic and nondiabetic subjects with and without symptomatic coronary artery disease (The Insulin Resistance Atherosclerosis Study). Am J Cardiol
2000;85:1395-400.
30. Wagenknecht LE, D'Agostino RB, Jr., Haffner SM, Savage PJ, Rewers M.
Impaired glucose tolerance, type 2 diabetes, and carotid wall thickness: the Insulin Resistance Atherosclerosis Study. Diabetes Care 1998;21:1812-8.
31. Sander GE, Giles TD. Diabetes mellitus and heart failure. Am Heart Hosp J 2003;1:273-80.
32. Kannel WB, Hjortland M, Castelli WP. Role of diabetes in congestive heart failure:
the Framingham study. Am J Cardiol 1974;34:29-34.
33. Shindler DM, Kostis JB, Yusuf S, et al. Diabetes mellitus, a predictor of morbidity and mortality in the Studies of Left Ventricular Dysfunction (SOLVD) Trials and Registry. Am J Cardiol 1996;77:1017-20.
34. Kamalesh M, Cleophas TJ. Heart failure due to systolic dysfunction and mortality in diabetes: pooled analysis of 39,505 subjects. J Card Fail 2009;15:305-9.
35. Standards of medical care in diabetes--2008. Diabetes Care 2008;31 Suppl 1:S12-54.
36. Krentz AJ, Bailey CJ. Oral antidiabetic agents: current role in type 2 diabetes mellitus. Drugs 2005;65:385-411.
37. Saenz A, Fernandez-Esteban I, Mataix A, Ausejo M, Roque M, Moher D.
Metformin monotherapy for type 2 diabetes mellitus. Cochrane Database Syst Rev 2005:CD002966.
38. Fisman EZ, Tenenbaum A, Motro M, Adler Y. Oral antidiabetic therapy in patients with heart disease. A cardiologic standpoint. Herz 2004;29:290-8.
39. Micormedex® Healthcare Series. Thomson Micromedex., 2009. (Accessed 5/22, 2009, at http://www.thomsonhc.com.)
40. Yki-Jarvinen H. Thiazolidinediones. N Engl J Med 2004;351:1106-18.
term survival after acute myocardial infarction in patients with diabetes mellitus.
DIGAMI (Diabetes Mellitus, Insulin Glucose Infusion in Acute Myocardial Infarction) Study Group. BMJ 1997;314:1512-5.
42. Doupis J, Veves A. DPP4 inhibitors: a new approach in diabetes treatment. Adv Ther 2008;25:627-43.
43. Ashcroft FM, Gribble FM. Tissue-specific effects of sulfonylureas: lessons from studies of cloned K(ATP) channels. J Diabetes Complications 2000;14:192-6.
44. Gribble FM, Reimann F. Sulphonylurea action revisited: the post-cloning era.
Diabetologia 2003;46:875-91.
45. Rendell M. The role of sulphonylureas in the management of type 2 diabetes mellitus. Drugs 2004;64:1339-58.
46. DeFronzo RA. Pharmacologic therapy for type 2 diabetes mellitus. Ann Intern Med 1999;131:281-303.
47. Pfeiffer AFH. Oral hypoglycemic agents: sulfonylureas and meglitinides. In:
Goldstein BJ, ed. Textbook of Type 2 Diabetes. 1 ed. United Kindon: Martin Dunitz;
2003.
48. Yildiz BO, Gurlek A. Failure of sulfonylureas in type 2 diabetes. Horm Metab Res 1999;31:293-4.
49. Anthont L McCall MCR. Combination therapy for treatment of type 2 diabetes. In:
Goldstein BJ, ed. Textbook of Type 2 Diabetes. 1 ed. United Kindon: Martin Dunitz;
2003.
50. DeFronzo RA, Goodman AM. Efficacy of metformin in patients with
non-insulin-dependent diabetes mellitus. The Multicenter Metformin Study Group. N Engl J Med 1995;333:541-9.
51. Riddle M. Combining sulfonylureas and other oral agents. Am J Med 2000;108 Suppl 6a:15S-22S.
52. Olsson J, Lindberg G, Gottsater M, et al. Increased mortality in Type II diabetic patients using sulphonylurea and metformin in combination: a population-based observational study. Diabetologia 2000;43:558-60.
53. Gulliford M, Latinovic R. Mortality in type 2 diabetic subjects prescribed
metformin and sulphonylurea drugs in combination: cohort study. Diabetes Metab Res Rev 2004;20:239-45.
54. Johnson JA, Majumdar SR, Simpson SH, Toth EL. Decreased mortality associated with the use of metformin compared with sulfonylurea monotherapy in type 2 diabetes.
Diabetes Care 2002;25:2244-8.
55. Rosenstock J. Insulin treatment in type 2 diabetes. United Kindon; 2003.
56. van Staa T, Abenhaim L, Monette J. Rates of hypoglycemia in users of sulfonylureas. J Clin Epidemiol 1997;50:735-41.
57. Gangji AS, Cukierman T, Gerstein HC, Goldsmith CH, Clase CM. A systematic review and meta-analysis of hypoglycemia and cardiovascular events: a comparison of glyburide with other secretagogues and with insulin. Diabetes Care 2007;30:389-94.
58. Miller CD, Phillips LS, Ziemer DC, Gallina DL, Cook CB, El-Kebbi IM.
Hypoglycemia in patients with type 2 diabetes mellitus. Arch Intern Med 2001;161:1653-9.
59. Holstein A, Plaschke A, Egberts EH. Clinical characterisation of severe
hypoglycaemia--a prospective population-based study. Exp Clin Endocrinol Diabetes 2003;111:364-9.
60. Management of hypoglycemia during treatment of diabetes mellitus UpToDate®, 2009. (Accessed 5/26, 2009, at http://www.utdol.com/home/index.html.)
61. Schernthaner G, Grimaldi A, Di Mario U, et al. GUIDE study: double-blind
comparison of once-daily gliclazide MR and glimepiride in type 2 diabetic patients. Eur J Clin Invest 2004;34:535-42.
62. Luis Bautista J, Bugos C, Dirnberger G, Atherton T. Efficacy and safety profile of glimepiride in Mexican American Patients with type 2 diabetes mellitus: a randomized, placebo-controlled study. Clin Ther 2003;25:194-209.
63. Meinert CL, Knatterud GL, Prout TE, Klimt CR. A study of the effects of
hypoglycemic agents on vascular complications in patients with adult-onset diabetes. II.
Mortality results. Diabetes 1970;19:Suppl:789-830.
64. Kilo C, Miller JP, Williamson JR. The Achilles heel of the University Group Diabetes Program. JAMA 1980;243:450-7.
65. Smits P, Bijlstra PJ, Russel FG, Lutterman JA, Thien T. Cardiovascular effects of sulphonylurea derivatives. Diabetes Res Clin Pract 1996;31 Suppl:S55-9.
66. Schotborgh CE, Wilde AA. Sulfonylurea derivatives in cardiovascular research and in cardiovascular patients. Cardiovasc Res 1997;34:73-80.
67. Negroni JA, Lascano EC, del Valle HF. Glibenclamide action on myocardial function and arrhythmia incidence in the healthy and diabetic heart. Cardiovasc Hematol Agents Med Chem 2007;5:43-53.
68. Toombs CF, Moore TL, Shebuski RJ. Limitation of infarct size in the rabbit by ischaemic preconditioning is reversible with glibenclamide. Cardiovasc Res
1993;27:617-22.
69. Lu H, Remeysen P, De Clerck F. The protection by ischemic preconditioning
ATP-sensitive potassium channels in rats. Coron Artery Dis 1993;4:649-57.
70. Kubota I, Yamaki M, Shibata T, Ikeno E, Hosoya Y, Tomoike H. Role of
ATP-sensitive K+ channel on ECG ST segment elevation during a bout of myocardial ischemia. A study on epicardial mapping in dogs. Circulation 1993;88:1845-51.
71. Huizar JF, Gonzalez LA, Alderman J, Smith HS. Sulfonylureas attenuate electrocardiographic ST-segment elevation during an acute myocardial infarction in diabetics. J Am Coll Cardiol 2003;42:1017-21.
72. Langtry HD, Balfour JA. Glimepiride. A review of its use in the management of type 2 diabetes mellitus. Drugs 1998;55:563-84.
73. Ischemic reperfusion injury of the heart. UpToDate®, 2009. (Accessed 5/30, 2009, at http://www.utdol.com/home/index.html.)
74. Cole WC, McPherson CD, Sontag D. ATP-regulated K+ channels protect the myocardium against ischemia/reperfusion damage. Circ Res 1991;69:571-81.
75. Shigematsu S, Sato T, Abe T, Saikawa T, Sakata T, Arita M. Pharmacological evidence for the persistent activation of ATP-sensitive K+ channels in early phase of reperfusion and its protective role against myocardial stunning. Circulation
1995;92:2266-75.
76. del Valle HF, Lascano EC, Negroni JA, Crottogini AJ. Glibenclamide effects on reperfusion-induced malignant arrhythmias and left ventricular mechanical recovery from stunning in conscious sheep. Cardiovasc Res 2001;50:474-85.
77. Thornton JD, Thornton CS, Sterling DL, Downey JM. Blockade of ATP-sensitive potassium channels increases infarct size but does not prevent preconditioning in rabbit hearts. Circ Res 1993;72:44-9.
78. Edwards G, Weston AH. Potassium channel openers and vascular smooth muscle relaxation. Pharmacol Ther 1990;48:237-58.
79. Samaha FF, Heineman FW, Ince C, Fleming J, Balaban RS. ATP-sensitive potassium channel is essential to maintain basal coronary vascular tone in vivo. Am J Physiol 1992;262:C1220-7.
80. Imamura Y, Tomoike H, Narishige T, Takahashi T, Kasuya H, Takeshita A.
Glibenclamide decreases basal coronary blood flow in anesthetized dogs. Am J Physiol 1992;263:H399-404.
81. Geisen K, Vegh A, Krause E, Papp JG. Cardiovascular effects of conventional sulfonylureas and glimepiride. Horm Metab Res 1996;28:496-507.
82. Billman GE. The cardiac sarcolemmal ATP-sensitive potassium channel as a novel target for anti-arrhythmic therapy. Pharmacol Ther 2008;120:54-70.
83. Billman GE, Avendano CE, Halliwill JR, Burroughs JM. The effects of the
ATP-dependent potassium channel antagonist, glyburide, on coronary blood flow and susceptibility to ventricular fibrillation in unanesthetized dogs. J Cardiovasc Pharmacol 1993;21:197-204.
84. Gribble FM, Reimann F. Differential selectivity of insulin secretagogues:
mechanisms, clinical implications, and drug interactions. J Diabetes Complications 2003;17:11-5.
85. Gribble FM, Tucker SJ, Seino S, Ashcroft FM. Tissue specificity of sulfonylureas:
studies on cloned cardiac and beta-cell K(ATP) channels. Diabetes 1998;47:1412-8.
86. Tomai F, Crea F, Gaspardone A, et al. Ischemic preconditioning during coronary angioplasty is prevented by glibenclamide, a selective ATP-sensitive K+ channel blocker. Circulation 1994;90:700-5.
87. Lee TM, Su SF, Chou TF, Lee YT, Tsai CH. Loss of preconditioning by attenuated activation of myocardial ATP-sensitive potassium channels in elderly patients
undergoing coronary angioplasty. Circulation 2002;105:334-40.
88. Klepzig H, Kober G, Matter C, et al. Sulfonylureas and ischaemic preconditioning;
a double-blind, placebo-controlled evaluation of glimepiride and glibenclamide. Eur Heart J 1999;20:439-46.
89. Scognamiglio R, Avogaro A, Vigili de Kreutzenberg S, et al. Effects of treatment with sulfonylurea drugs or insulin on ischemia-induced myocardial dysfunction in type 2 diabetes. Diabetes 2002;51:808-12.
90. Reffelmann T, Klues HG, Hanrath P, Schwarz ER. Post-stenotic coronary blood flow at rest is not altered by therapeutic doses of the oral antidiabetic drug
glibenclamide in patients with coronary artery disease. Heart 2002;87:54-60.
91. Bijlstra PJ, Lutterman JA, Russel FG, Thien T, Smits P. Interaction of
sulphonylurea derivatives with vascular ATP-sensitive potassium channels in humans.
Diabetologia 1996;39:1083-90.
92. Chan JC, Tomlinson B, Critchley JA, Cockram CS, Walden RJ. Metabolic and hemodynamic effects of metformin and glibenclamide in normotensive NIDDM patients. Diabetes Care 1993;16:1035-8.
93. Wysowski DK, Armstrong G, Governale L. Rapid increase in the use of oral antidiabetic drugs in the United States, 1990-2001. Diabetes Care 2003;26:1852-5.
94. Davis TM, Parsons RW, Broadhurst RJ, Hobbs MS, Jamrozik K. Arrhythmias and mortality after myocardial infarction in diabetic patients. Relationship to diabetes treatment. Diabetes Care 1998;21:637-40.
95. Halkin A, Roth A, Jonas M, Behar S. Sulfonylureas are not associated with
infarction. J Thromb Thrombolysis 2001;12:177-84.
96. Danchin N, Charpentier G, Ledru F, et al. Role of previous treatment with sulfonylureas in diabetic patients with acute myocardial infarction: results from a nationwide French registry. Diabetes Metab Res Rev 2005;21:143-9.
97. Horsdal HT, Johnsen SP, Sondergaard F, et al. Sulfonylureas and prognosis after myocardial infarction in patients with diabetes: a population-based follow-up study.
Diabetes Metab Res Rev 2009.
98. Jollis JG, Simpson RJ, Jr., Cascio WE, Chowdhury MK, Crouse JR, 3rd, Smith SC, Jr. Relation between sulfonylurea therapy, complications, and outcome for elderly patients with acute myocardial infarction. Am Heart J 1999;138:S376-80.
99. Garratt KN, Brady PA, Hassinger NL, Grill DE, Terzic A, Holmes DR, Jr.
Sulfonylurea drugs increase early mortality in patients with diabetes mellitus after direct angioplasty for acute myocardial infarction. J Am Coll Cardiol 1999;33:119-24.
100. Brady PA, Al-Suwaidi J, Kopecky SL, Terzic A. Sulfonylureas and mortality in diabetic patients after myocardial infarction. Circulation 1998;97:709-10.
101. Fisman EZ, Tenenbaum A, Boyko V, et al. Oral antidiabetic treatment in patients with coronary disease: time-related increased mortality on combined
glyburide/metformin therapy over a 7.7-year follow-up. Clin Cardiol 2001;24:151-8.
102. Evans JM, Ogston SA, Emslie-Smith A, Morris AD. Risk of mortality and adverse cardiovascular outcomes in type 2 diabetes: a comparison of patients treated with sulfonylureas and metformin. Diabetologia 2006;49:930-6.
103. Simpson SH, Majumdar SR, Tsuyuki RT, Eurich DT, Johnson JA. Dose-response relation between sulfonylurea drugs and mortality in type 2 diabetes mellitus: a
population-based cohort study. CMAJ 2006;174:169-74.
104. Margolis DJ, Hoffstad O, Strom BL. Association between serious ischemic cardiac outcomes and medications used to treat diabetes. Pharmacoepidemiol Drug Saf
2008;17:753-9.
105. Evans JM, Ogston SA, Reimann F, Gribble FM, Morris AD, Pearson ER. No differences in mortality between users of pancreatic-specific and
non-pancreatic-specific sulphonylureas: a cohort analysis. Diabetes Obes Metab 2008;10:350-2.
106. Aronow WS, Ahn C. Incidence of new coronary events in older persons with diabetes mellitus and prior myocardial infarction treated with sulfonylureas, insulin, metformin, and diet alone. Am J Cardiol 2001;88:556-7.
107. International Diabetes Federation. 2009. (Accessed 6/1, 2009, at
http://www.idf.org/diabetes-prevalence.)
108. Chou P, Li CL, Tsai ST. Epidemiology of type 2 diabetes in Taiwan. Diabetes Res Clin Pract 2001;54 Suppl 1:S29-35.
109. Nathan DM, Buse JB, Davidson MB, et al. Management of hyperglycemia in type 2 diabetes: A consensus algorithm for the initiation and adjustment of therapy: a
consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 2006;29:1963-72.
110. Chiang CW, Chiu HF, Chen CY, Wu HL, Yang CY. Trends in the use of oral antidiabetic drugs by outpatients in Taiwan: 1997-2003. J Clin Pharm Ther
2006;31:73-82.
111. 全民健康保險資料庫藥品檔(DRUG2006). In. Taiwan: 國家衛生研究院; 2006.
112. Del Prato S, Pulizzi N. The place of sulfonylureas in the therapy for type 2 diabetes mellitus. Metabolism 2006;55:S20-7.
113. Chuang LM, Tsai ST, Huang BY, Tai TY. The current state of diabetes management in Taiwan. Diabetes Res Clin Pract 2001;54 Suppl 1:S55-65.
114. McAfee AT, Koro C, Landon J, Ziyadeh N, Walker AM. Coronary heart disease outcomes in patients receiving antidiabetic agents. Pharmacoepidemiol Drug Saf 2007;16:711-25.
115. Walker AM, Koro CE, Landon J. Coronary heart disease outcomes in patients receiving antidiabetic agents in the PharMetrics database 2000-2007.
Pharmacoepidemiol Drug Saf 2008;17:760-8.
116. Monami M, Balzi D, Lamanna C, et al. Are sulphonylureas all the same? A cohort
116. Monami M, Balzi D, Lamanna C, et al. Are sulphonylureas all the same? A cohort